IDO level increase in Kynurenine Pathway Contributes to the Development of Alzheimer's Disease
Authors: 
Ziyu Xue, Yiran Yang, Borui Li, Wenrui Li, Jiani Chen, Yue PanAuthors Info & Claims
Ziyu Xue, Yiran Yang, Borui Li, Wenrui Li, Jiani Chen, Yue PanAuthors Info & ClaimsPages 344 - 349
Abstract
Tryptophan is crucial to many functions of the body. Research has shown that its involvement in the Kynurenine pathway (KP) also plays a role in the development of various neurodegenerative diseases (ND). As one of the upstream enzymes in KP, Indoleamine 2,3-dioxygenase (IDO) controls the production of several critical downstream metabolites. Some of these metabolites, such as kynurenic acid (KYNA), possess neuroprotective properties, while some other, such as quinolinic acid (QUIN) are neurotoxic. Hence, the balance between these species is closely linked to the pathogenesis of NDs. Interesting, a positive association has also been found between the level of IDO and the level of amyloid peptide Aβ1-42 involved in Alzheimer's disease. Therefore, this experiment aims to investigate the mechanistic link between increases in levels of IDO and beta-amyloid production. We hypothesize that an increase in IDO level caused by systemic inflammation promotes the generation of key markers of AD by causing an imbalance in levels of tryptophan metabolites, specifically by shifting towards production of neurotoxic metabolite (QUIN) over neuroprotective species (KYNA).
References
[1]
Encyclopedia, Medical. "Tryptophan: Medlineplus Medical Encyclopedia". Medlineplus.Gov, 2022, https://medlineplus.gov/ency/article/002332.htm#:∼:text=Tryptophan%20is%20an%20amino%20acid,get%20it%20from%20your%20diet.
[2]
Pubchem.Ncbi.Nlm.Nih.Gov. 2022. Tryptophan.https://pubchem.ncbi.nlm.nih.gov/compound/Tryptophan
[3]
"IDO1 Indoleamine 2,3-Dioxygenase 1 [Homo Sapiens (Human)] - Gene - NCBI". Ncbi.Nlm.Nih.Gov, 2022, https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermTo Search=3620.
[4]
Chen, WanJun. "IDO: More Than An Enzyme". Nature Immunology, vol 12, no. 9, 2011, pp. 809-811. Springer Science And Business Media LLC.
[5]
"Sandwich ELISA Principles, Formats, And Optimization". Genscript.Com, 2022, https://www.genscript.com/ELISA-Principles-Formats-and-Optimization.html.
[6]
Schmidt, Stephen D. "ELISA Method For Measurement Of Amyloid-Β Levels". 2004. Amyloid Proteins, pp. 279-298. Humana Press.
[7]
Ishibashi, A., Saga, K., Hisatomi, Y. A simple method using CRISPR-Cas9 to knock-out genes in murine cancerous cell lines. Sci Rep 10, 22345. 2020. https://doi.org/10.1038/s41598-020-79303-0
[8]
Thomas J. Connor a,∗, Neasa Starr a, Joan B. O'Sullivana, Andrew Harkinb. "Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-y? "© 2008. Elsevier Ireland Ltd.
[9]
Xia, Weiming “A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease.” Archives of neurology vol. 66,2. 2009: 190-9.
[10]
Dantzer, R., Zhou, W., Laumet, G. Neuroimmune Mechanisms of Comorbid Chronic Pain and Depression. Biological Psychiatry 81(10): S14-S15. 2017.
Index Terms
- IDO level increase in Kynurenine Pathway Contributes to the Development of Alzheimer's Disease
Index terms have been assigned to the content through auto-classification.
Recommendations
Bioinformatics-Based Acquisition of Alzheimer’s Disease Hub Genes
Big Data – BigData 2023AbstractOBJECTIVE: To analyze the functions and pathways of differentially expressed genes (DEGs) between Alzheimer’s disease (AD) patients and normal controls using bioinformatics methods, and to screen Hub genes to provide theoretical support for the ...
Identifying potential Alzheimer's disease therapeutics through GSK-3β inhibition: A molecular docking and dynamics approach
AbstractEmerging as a promising drug target for Alzheimer's disease (AD) therapy, glycogen synthase kinase 3β (GSK-3β) has garnered attention. This study sought to rigorously scrutinize a compendium of natural compounds retrieved from the ZINC database ...
Graphical AbstractDisplay Omitted
Highlights- We used molecular docking and dynamics to find natural compounds inhibiting gsk-3β, a target for Alzheimer's therapy.
- Utilized a multi-step computational approach, including pharmacophore analysis, docking, and ESMACS simulations, to ...
Comments
Information & Contributors
Information
Published In
October 2022
594 pages
ISBN:9781450398442
DOI:10.1145/3570773
Copyright © 2022 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 09 December 2022
Check for updates
Qualifiers
- Research-article
- Research
- Refereed limited
Conference
ISAIMS 2022
ISAIMS 2022: 2022 3rd International Symposium on Artificial Intelligence for Medicine Sciences
October 13 - 15, 2022
Amsterdam, Netherlands
Acceptance Rates
Overall Acceptance Rate 53 of 112 submissions, 47%
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 40Total Downloads
- Downloads (Last 12 months)17
- Downloads (Last 6 weeks)1
Reflects downloads up to 25 Feb 2025
Other Metrics
Citations
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign inFull Access
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML Format